Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 6/2017

01-12-2017 | Case Report

Unusually high levels of serum p53 antibody in recurrent gastric cancer

Authors: Masaki Kunizaki, Keiko Hamasaki, Kouki Wakata, Shigekazu Hidaka, Takeshi Nagayasu, Yukie Kinoshita

Published in: Clinical Journal of Gastroenterology | Issue 6/2017

Login to get access

Abstract

Serum tumor markers in patients with cancer assist with establishing diagnosis, estimating prognosis, monitoring treatment, and detecting tumor recurrence. Changes in the p53 tumor suppressor gene are the most common genetic abnormalities in many different human malignancies. Several studies have demonstrated that serum p53 antibodies (S-p53Ab) comprise an early marker of malignant disease, a marker for treatment effects and a prognostic factor for patients with several types of tumors. We recently reported that S-p53Ab is useful for patients with gastric cancer. We describe a rare situation in which unusually high serum p53 antibodies helped to detect recurrent gastric cancer in the small intestine after gastrectomy. Further studies are required to gain a more precise understanding of the clinical impact of S-p53Ab titer monitoring in gastric cancer.
Literature
1.
2.
go back to reference Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–9.PubMed Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–9.PubMed
3.
go back to reference Yachida S, White CM, Naito Y, et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res. 2012;18(22):6339–47.CrossRefPubMedPubMedCentral Yachida S, White CM, Naito Y, et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res. 2012;18(22):6339–47.CrossRefPubMedPubMedCentral
4.
go back to reference Kunizaki M, Sawai T, Takeshita H, et al. Clinical value of serum p53 antibody in the diagnosis and prognosis of colorectal cancer. Anticancer Res. 2016;36(8):4171–5.PubMed Kunizaki M, Sawai T, Takeshita H, et al. Clinical value of serum p53 antibody in the diagnosis and prognosis of colorectal cancer. Anticancer Res. 2016;36(8):4171–5.PubMed
5.
go back to reference Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors. Cancer. 2013;97(3):682–9.CrossRef Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors. Cancer. 2013;97(3):682–9.CrossRef
6.
go back to reference Ochiai H, Ohishi T, Osumi K, et al. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today. 2012;42:164–8.CrossRefPubMed Ochiai H, Ohishi T, Osumi K, et al. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today. 2012;42:164–8.CrossRefPubMed
7.
go back to reference Wu CW, Lin YY, Chen GD, et al. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br J Cancer. 1999;80:483–8.CrossRefPubMedPubMedCentral Wu CW, Lin YY, Chen GD, et al. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br J Cancer. 1999;80:483–8.CrossRefPubMedPubMedCentral
8.
go back to reference Shimada H, Shiratori T, Takeda A, et al. Preoperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33:272–7.CrossRefPubMed Shimada H, Shiratori T, Takeda A, et al. Preoperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33:272–7.CrossRefPubMed
9.
10.
go back to reference Kunizaki M, Fukuda A, Wakata K, et al. Clinical significance of serum p53 antibody in the early detection and poor prognosis of gastric cancer. Anticancer Res. 2017;37(4):1979–84.CrossRefPubMed Kunizaki M, Fukuda A, Wakata K, et al. Clinical significance of serum p53 antibody in the early detection and poor prognosis of gastric cancer. Anticancer Res. 2017;37(4):1979–84.CrossRefPubMed
11.
go back to reference Suzuki T, Shimada H, Ushigome M, et al. Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer. Clin J Gastroenterol. 2016;9:55–8.CrossRefPubMed Suzuki T, Shimada H, Ushigome M, et al. Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer. Clin J Gastroenterol. 2016;9:55–8.CrossRefPubMed
Metadata
Title
Unusually high levels of serum p53 antibody in recurrent gastric cancer
Authors
Masaki Kunizaki
Keiko Hamasaki
Kouki Wakata
Shigekazu Hidaka
Takeshi Nagayasu
Yukie Kinoshita
Publication date
01-12-2017
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 6/2017
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-017-0780-x

Other articles of this Issue 6/2017

Clinical Journal of Gastroenterology 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.